Nusano
West Valley City, Utah, United States · Biotechnology, Health Care, Information Technology · 1,000 employees
Nusano is a medical technology company that creates radioisotopes—tiny tracers used by doctors to diagnose and treat cancer and other diseases. Doctors use these tiny tracers like flashlights to light up areas inside the body. They can see how blood is flowing, how organs are functioning, even how cells are growing. Advanced medicines and treatment methods also use radioisotopes to target and elim
Funding history
- Series series c — $115.0M — Oct 2024
- Funding Round — $10.0M — Nov 2022
- Funding Round — $48.0M — Sep 2021
- Funding Round — $41.5M — Oct 2018
- Series seed — $800K — Nov 2017
Recent signals
- Oct 14, 2025: Nusano and Ariceum Therapeutics Forge Multi-Isotope Supply Agreement to Enhance Cancer Treatment Options.
- Jun 27, 2025: Nusano and Cellectar Biosciences Enter Multi-Year Isotope Supply Agreement to Support Cancer Drug Development
- Dec 03, 2024: Launched Nusano Establishes Medical Radioisotopes Advisory Board to Enhance Cancer Therapy Development.
- Oct 01, 2024: Raised $115.0M in Series series c
- Oct 01, 2024: Nusano Announces Series C Financing of Over $115M with The Wasatch Group and S32
- Jan 22, 2024: Nusano Names Rohan Jain as Commercial General Manager
- Sep 15, 2023: Nusano Appoints Industry Expert Alexandre Gibim as Chief
- Nov 04, 2022: Raised $10.0M
See plans & pricing → Track Nusano’s funding, hiring, and signals — with verified contacts — on Fundz.